Tag: IHL
Incannex Healthcare recruits for IHL-42X obstructive sleep apnoea clinical trial
On a path to developing a suite of cannabinoid-based medicines aimed at remedying a range of debilitating conditions, pharmaceutical development company Incannex Healthcare (ASX: IHL) has recruited th...
Pre-clinical research of Incannex Healthcare’s IHL-216A drug found it effective preventing traumatic brain injury
Incannex Healthcare (ASX: IHL) has revealed more positive in vivo research for its IHL-216A drug, this time regarding traumatic brain injury and has filed a patent application to cover this intellectu...
Incannex Healthcare and Monash University to undertake ‘world first’ trial using psilocybin mushrooms to treat anxiety
Incannex Healthcare (ASX: IHL) has partnered with Monash University to undertake a “world first” clinical trial using psilocybin-assisted psychotherapy to treat generalised anxiety disorder.
Accord...
Incannex Healthcare reveals positive in vivo results, will call Pre-IND meeting with FDA
Cannabinoid development company Incannex Healthcare (ASX: IHL) has unveiled the latest test results of its lead drug candidate IHL-675A, which show its anti-inflammatory potency make it an excellent c...
Incannex Healthcare enters trading halt ahead of study results and FDA strategy
Cannabinoid drug development company Incannex Healthcare (ASX: IHL) could be on the cusp of announcing a significant development in its mission to develop workable cannabinoid treatments for a range o...
Incannex lead drug candidate exhibits stronger anti-inflammatory action than CBD in preclinical studies
Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has received positive results from pre-clinical in vitro studies into the anti-inflammatory potency of its lead drug IHL-6...
Incannex achieves record medicinal cannabis oil sales as pure play pharmaceutical company
Incannex (ASX: IHL) has reported its highest quarterly sales for the September period – beating its previous June quarter record.
For the three months ending September 2020, Incannex received $695,...
Incannex receives ethics approval for novel cannabinoid in phase 2b obstructive sleep apnoea trial
Incannex Healthcare (ASX: IHL) has received ethics approval for a phase 2b clinical trial to study the therapeutic benefits of its lead drug IHL-42X on patients with obstructive sleep apnoea (OSA).
...
Incannex announces in vitro results from sepsis-associated acute respiratory disease drug studies
Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has announced positive preliminary results on the anti-inflammatory activity of lead drug IHL-675A against sepsis-associat...
Incannex commences animal trial to establish optimal dosage of IHL-216A in treating traumatic brain injuries
Cannabinoid development company Incannex Healthcare (ASX: IHL) has commenced a pre-clinical animal trial investigating the neuroprotective capabilities of its lead candidate IHL-216A.
The trial wil...
Incannex reports positive results from animal study into CBD-based drug for ARDS resulting from COVID-19
After reporting amiable progress concerning its sleep apnoea drug IHL-42X just last week, cannabinoid drug development company Incannex Healthcare (ASX: IHL) has published positive results from its an...
Incannex partners with The Alfred Hospital for clinical trial to study impact of cannabinoid drug on patients with obstructive sleep apn...
Clinical stage cannabinoid development company Incannex Healthcare (ASX: IHL) has partnered with The Alfred Hospital in Melbourne for a phase 2b dose finding crossover trial investigating the effect o...
Incannex Healthcare shifts from making an impression to setting sales records
Cannabinoid development company Incannex Healthcare (ASX: IHL) has published provisional performance figures for the past quarter, declaring a “record” three months with sales momentum expected to con...
Impression Healthcare to focus exclusively on cannabinoid sales and drug development
Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales an...
Impression Healthcare starts CBD drug trial to fight leading cause of COVID-19 deaths
Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A against sepsis associated acute respiratory distress syndro...
Impression Healthcare recruits NRL star James Graham to boost commercial development of IHL-216A
Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footballer James Graham.
In a statement to the market this m...
Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions
Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A de...
Impression Healthcare targets 2024 commercialisation of cannabinoid treatment for traumatic brain injury
Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with traumatic brain injury to the prescription market within...
Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms
Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress ...
Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X
Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X from US-based Cama...
Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme
Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose inhalers (similar to an...
